Skip to content

Released Nov 4, 2024, after the close

10-Q filed Nov 4, 2024, 35 days after period end · 0001628280-24-045006

Q3 2024 · 10-Q
Revenue$7.81M−55.3% vs Q3 2023+13.4% vs Q2 2024
Net Income-$19.12MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.31N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$23,852,000N/M
Operating Cash Flowderived-$21,005,000N/M
Free Cash Flowderived-$21,314,000N/M
Margins · derived
Operating margin-305.5%−207.8 pt vs Q3 2023
Net margin-244.9%−162.8 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$7.81M$17.48M$6.63M$41.00K
Net Income-$19.12M-$14.35M-$25.77M-$26.08M
EPS Diluted-$0.31-$0.34-$0.62-$0.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR